Abstract:Circulation Research, Ahead of Print. BACKGROUND:Cardiac hypertrophy is an adaptive response to pressure overload aimed at maintaining cardiac function. However, prolonged hypertrophy significantly increases the risk of maladaptive cardiac remodeling and heart failure. Recent studies have implicated long noncoding RNAs in cardiac hypertrophy and cardiomyopathy, but their significance and mechanism(s) of action are not well understood.METHODS:We measuredlincRNA-p21RNA and H3K27ac levels in the hearts of dilated cardiomyopathy patients. We assessed the functional role oflincRNA-p21in basal and surgical pressure-overload conditions using loss-of-function mice. Genome-wide transcriptome analysis revealed dysregulated genes and pathways. We labeled proteins in proximity to full-lengthlincRNA-p21using a novel BioID2-based system. We immunoprecipitatedlincRNA-p21-interacting proteins and performed cell fractionation, ChIP-seq (chromatin immunoprecipitation followed by sequencing), and co-immunoprecipitation to investigate molecular interactions and underlying mechanisms. We used GapmeR antisense oligonucleotides to evaluate the therapeutic potential oflincRNA-p21inhibition in cardiac hypertrophy and associated heart failure.RESULTS:lincRNA-p21was induced in mice and humans with cardiomyopathy. Global and cardiac-specificlincRNA-p21knockout significantly suppressed pressure overload-induced ventricular wall thickening, stress marker elevation, and deterioration of cardiac function. Genome-wide transcriptome analysis and transcriptional network analysis revealed thatlincRNA-p21actsin transto stimulate the NFAT/MEF2 pathway. Mechanistically,lincRNA-p21is bound to the scaffold protein KAP1.lincRNA-p21cardiac-specific knockout suppressed stress-induced nuclear accumulation of KAP1, and KAP1 knockdown attenuated cardiac hypertrophy and NFAT activation. KAP1 positively regulates pathological hypertrophy by physically interacting with NFATC4 to promote the overactive status of NFAT/MEF2 signaling. GapmeR antisense oligonucleotide depletion oflincRNA-p21similarly inhibited cardiac hypertrophy and adverse remodeling, highlighting the therapeutic potential of inhibitinglincRNA-p21.CONCLUSIONS:These findings advance our understanding of the functional significance of stress-induced long noncoding RNA in cardiac hypertrophy and demonstrate the potential oflincRNA-p21as a novel therapeutic target for cardiac hypertrophy and subsequent heart failure.

O Knockdown de LncRNA CCAT2 Alivia a Sobrecarga de Pressão ou a Hipertrofia Cardíaca Induzida por Ang II por Meio da Interrupção da Sinalização Wnt/β-catenina

LncRNA CCAT2 Knockdown Alleviates Pressure Overload or Ang II-Induced Cardiac Hypertrophy Via Disruption of the Wnt/β-Catenin Signaling.

LncRNA TUG1 Alleviates Cardiac Hypertrophy by Targeting Mir‐34a/dkk1/wnt‐β‐catenin Signalling

Aliskiren Ameliorates Pressure Overload-Induced Heart Hypertrophy and Fibrosis in Mice

Knockdown of CD146 Promotes Endothelial-to-mesenchymal Transition Via Wnt/β-catenin Pathway

lncRNA NBR2 attenuates angiotensin II-induced myocardial hypertrophy through repressing ER stress via activating LKB1/AMPK/Sirt1 pathway

LTBP2 Knockdown Ameliorates Cardiac Fibrosis and Apoptosis via Attenuating NF‐κB Signaling Pathway and Oxidative Stress in Mice with Cardiac Hypertrophy

NSD2 promotes pressure overload-induced cardiac hypertrophy via activating circCmiss1/TfR1/ferroptosis signaling

Angiotensin II prompts heart cell apoptosis via AT1 receptor-augmented phosphatase and tensin homolog and miR-320-3p functions to enhance suppression of the IGF1R-PI3K-AKT survival pathway

Circular RNA circRNA_000203 aggravates cardiac hypertrophy via suppressing miR-26b-5p and miR-140-3p binding to Gata4

Ccn2 Deletion Reduces Cardiac Dysfunction, Oxidative Markers, and Fibrosis Induced by Doxorubicin Administration in Mice

CD1d-dependent natural killer T cells attenuate angiotensin II-induced cardiac remodelling via IL-10 signalling in mice

The role of lncRNAKCNQ1OT1/miR-301b/Tcf7 axis in cardiac hypertrophy

Therapeutic Inhibition of LincRNA-p21 Protects Against Cardiac Hypertrophy

LncRNA ENSMUST00000155383 is Involved in the Improvement of DPP-4 Inhibitor MK-626 on Vascular Endothelial Function by Modulating Cacna1c-Mediated Ca<SUP>2+</SUP> Influx in Hypertensive Mice

LncRNA TINCR attenuates cardiac hypertrophy by epigenetically silencing CaMKII.

LncRNA ENSMUST00000155383 is Involved in the Improvement of DPP-4 Inhibitor MK-626 on Vascular Endothelial Function by Modulating Cacna1c-Mediated Ca2+ Influx in Hypertensive Mice

Identification of a long noncoding RNA Gm17501 as a novel negative regulator of cardiac hypertrophy

Inhibition of long noncoding RNA Gm41724 alleviates pressure overload-induced cardiac fibrosis by regulating lamina-associated polypeptide 2α

Cardiac-specific knockdown of Bhlhe40 attenuates angiotensin II (Ang II)-Induced atrial fibrillation in mice

Long noncoding RNA AK144717 exacerbates pathological cardiac hypertrophy through modulating the cellular distribution of HMGB1 and subsequent DNA damage response